Auryxia
(ferric citrate)Phase 3Small molecule
Ferric citrate is used to treat high phosphorus levels in the blood in patients with kidney disease, and it also helps treat iron deficiency anemia in people with chronic kidney disease who are on dialysis.[1] Auryxia is currently being investigated across 4 indications[3], with its most advanced program in Phase 3.[1]
Auryxia is one of 117 small molecule programs targeting Iron deficiency anemia. It is currently in Phase 3.
4
Indications
20
Total Trials
3
Active Trials
116
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
540 competitors in Chronic Kidney Disease
#DrugCompanyPhaseTrials
1Auryxia
KKeryx Biopharmaceuticals
Phase 3
Aranesp
AmgenPreclinical
Epogen
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Preclinical
Uloric
TakedaPreclinical
Sovaldi
GileadPreclinical
Glucotrol
PfizerPreclinical
Flomax
SanofiPreclinical
Activase
RochePreclinical
Miochol
BBausch Health Americas, Inc.
Preclinical
Epoetin Beta
RochePreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Chronic Kidney Disease6 trials
End-Stage Renal Disease3 trials
End Stage Renal Disease (ESRD)3 trials
Peritoneal Dialysis1 trial
6 more indications
Iron-deficiency1 trial
Adult Subject1 trial
Iron deficiency anemia1 trial
Ferric Citrate in Iron Deficiency Anemia During Pregnancy
Not yet recruiting·—·Phase 3·NCT07381426·680 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for ferric citrate. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- KKeryx Biopharmaceuticals